| Name | Drozitumab |
|---|
| Description | Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Drozitumab selectively eliminates cancer stem cells (CSCs), resulting in tumor growth inhibition and even regression of pancreatic tumors[3]. Drozitumab induces apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes[1]. |
| References |
| Molecular Weight | 143.1 (kDa) |
|---|